However, a recent work in acute lymphoblastic leukemia has demonstrated that upon Dex treatment, this specific enhancer promotes an active chromatin interaction with the BCL2L11 promoter to up-regulate gene transcription (Jing et al, 2018). Here, BCL2L11 is linked to acute lymphoblastic leukemia.